APA (7th ed.) Citation

L, S., Y, Z., Z, L., X, Z., X, G., B, L., . . . J, J. (2025). Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nature medicine, 31(4), 1368. https://doi.org/10.1038/s41591-025-03666-y

Chicago Style (17th ed.) Citation

L, Shen, et al. "Author Correction: First-line Cadonilimab Plus Chemotherapy in HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-blind, Phase 3 Trial." Nature Medicine 31, no. 4 (2025): 1368. https://doi.org/10.1038/s41591-025-03666-y.

MLA (9th ed.) Citation

L, Shen, et al. "Author Correction: First-line Cadonilimab Plus Chemotherapy in HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-blind, Phase 3 Trial." Nature Medicine, vol. 31, no. 4, 2025, p. 1368, https://doi.org/10.1038/s41591-025-03666-y.